The United States is experiencing an opioid epidemic, and there were about 130 opioid overdose deaths each day, 10.3M misused opioid prescriptions and 2 million patients with opioid misuse disorder each year.
With he advent of low-cost sequencing, multi-omics is expected to become clinical routine and transform precision oncology within next decade. However, viable multi-omics models that can facilitate clinical decisions and tolerate sequencing bias are far lacking.
Persuasive languages present several unique challenges to the automatic processing of text. Common rhetorical devices used for persuasion are non-literal and implicit, so systems need to be able to disambiguate metaphoric usages and recognize the underlying intentions in text.
Mobile health applications (mHealth apps) are an integral part of the healthcare information ecology, with individuals using apps to track their health and manage health-related problems and healthcare organizations working to identify ways to incorporate this data into healthcare workflow. The degree to which mHealth apps adhere to well-established general good design principles or incorporate user-centered design approaches varies widely.
Healthcare providers nationwide have spent billions of dollars adopting electronic health records (EHRs) that incorporate clinical decision support (CDS) to improve patient safety, reduce costs, and comply with federal regulations. EHR adoption is nearly universal, 95% of EHRs in use are commercially-developed systems, and CDS is becoming interoperable across institutions and EHRs.
Dr. Foraker will share her experience implementing and evaluating health information technology tools in the context of cancer survivorship, with a focus on tool development and study design.
In this talk, the speaker will outline some of the challenges and opportunities of medical imaging AI in research and clinical translation, illustrate how a convergence approach will be helping address some of the barriers, and showcase a variety of AI research projects.
In this talk, translational pharmacoinformatics methods will be presented for the drug interaction research. They include literature based drug interaction discovery, drug interaction signal data mining from health record databases, translational drug interaction and pharmacogenetics studies, drug interaction knowledgebase for cancer phase I clinical trials, and target combination discovery for breast cancer chemo or PARP1 inhibitor resistance.
The era of designs for clinical trials using Bayesian principles begins in 1990 with the publication of the Continual Reassessment Method, but until the mid 1990s, with the dissemination of flexible and powerful Markov Chain Monte Carlo software, only very simple models or models using conjugate priors were feasible. Since then, the landscape has changed considerably and now it is possible to design clinical trials that adapt to accumulating data using mathematical mod